At the heart of our social responsibility
Ethics & Transparency are the core of the company’s social responsibility. It is our way of working every day and forms the basis of our relationship with each of our stakeholders.
We strongly believe that Ethics & Transparency are real drivers of value creation, essential and undisputed to preserve and strengthen the trust of patients, stakeholders and communities.
We have developed strong rules in accordance with the legal framework in each of the countries we operate in. Our Code of Ethics is available in 29 languages and provided to all employees
Medical ethics and bioethics: responsible practices and progress
Continuously revisiting and improving consistent and transparent bioethical standards throughout our research and clinical development activities, our Chief Medical Officer and Global Head of Medical Function who reports to the Chief Executive Officer, chairs the Sanofi Bioethics Committee. The Bioethics Committee determines our position on bioethics policies and ensures ethical conduct for Sanofi medical and scientific activities.
With new biotechnologies, scientific advances, public health priorities, stronger demand for transparency and data protection, we constantly improve and upgrade our ethical requirement in clinical research. We regularly issue and update our policies.
- For more information on Medical ethics and bioethics
The company also focuses on the ethical challenges regarding the use of animals in research and production of drugs and vaccines. The current consensus is that using animals for research and production is justified when there are clear benefits for human health and when the 3Rs principles (replacement, reduction and refinement of animal use) are applied.
Over a two-year period, we decreased by almost 12% the use of animals through improvements and the development of new techniques.
Because we are committed to credibility and trust, Transparency is the cornerstone of our strategy. We disclose our investments to healthcare professionals, all ongoing clinical study protocols are available and we publish our study results, both positive and negative.
- Interactions with healthcare providers, healthcare organizations and medical and scientific associations.
Public disclosure in 40 countries of our interactions with healthcare professionals and medical and scientific associations
Relations with healthcare professionals
- Clinical trials data transparency.
43 clinical trial registrations and 142 clinical trial results posted in 2016
Clinical trials disclosures commitments
Our contribution to scientific research is ongoing and strong.
We have authored or sponsored 611 scientific and medical publications in PubMed with over 5,600 journals indexed.
Also, we received 37 requests from eleven countries for clinical trial data sharing for 92 clinical trials since 2014.
Business ethics: do the right thing, the right way, at the right time and for the right reason
Supported by all departments, the Ethics & Business Integrity (E&BI) Department is a cornerstone of Sanofi’s ethical approach, supporting the achievement of our business objectives while ensuring compliance and promoting business ethical values in daily activities.
We have developed a Code of Ethics addressing 13 topics supported by dedicated policies and procedures (e.g. anti-bribery policy, patient advocates and groups, donations,…).
A Compliance Helpline system has been implemented to allow anyone to raise concerns directly to Ethics & Business Integrity department if they believe in good faith that the Sanofi Code of Ethics, policies and standards or a law, regulation, an industry code of conduct has been or is about to be violated.
In 2016, over 190,000 Ethics & Business integrity training modules were followed by our employees worldwide.
Responsible procurement : creating value through the supply chain
We have developed an innovative supplier risk management model based upon risk mapping procurement category and risk exposure mapping per country. In 2016, we joined the Together for Sustainability initiative. We are also an active member of the Pharmaceutical Supply Chain Initiative through two major programs (Supplier Shared Audit and Supplier Performance Improvement).
We believe that being part of these collaborative initiatives will improve our capability, along with our suppliers, to uphold our CSR commitments.
We have conducted 86 audits in 2016 and 473 supplier assessments since 2014.
Patient safety: first
Patient safety is the primary focus of our Global Pharmacovigilance, Quality and Counterfeiting teams. We aim to guarantee quality at each phase of a product’s life cycle.
Our commitment to quality comes first. We constantly monitor and improve our quality management, globally and locally. Our quality management encompasses: quality systems, inspection readiness, quality risk management, quality performance and quality culture
Close to 94,000 employees trained through “The Quality Fundamentals” e-learning program.
365 regulatory inspections in 2016.
We monitor product safety and constantly assess the benefit-risk profile of our products in close relation with health authorities. The best conditions of their use are provided to physicians, healthcare professionals and patients with comprehensive up-to-date information.
Our Global Pharmacovigilance department has set up an effective global organization to collect pharmacovigilance data from all sources of information with strong interactions with stakeholders worldwide.